期刊
EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES
卷 29, 期 -, 页码 -出版社
CAMBRIDGE UNIV PRESS
DOI: 10.1017/S2045796019000751
关键词
Esketamine; evidence-based medicine; FDA; regulatory policies; treatment-resistant depression
类别
In March 2019, the US Food and Drug Administration (FDA) approved a nasal spray formulation of esketamine for the treatment of resistant depression in adults. Esketamine is the S-enantiomer of ketamine, an FDA-approved anaesthetic, known to cause dissociation and, occasionally, hallucinations. While ketamine has not been approved for depression in the USA or in any other country, it has been used off-label in cases of severe depression. This commentary critically reviewed the evidence on esketamine submitted to the FDA, aiming to draw implications for clinical practice, research and regulatory science.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据